Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Preferred Stock Liabilities (2024)

Caris Life Sciences (CAI) has 1 years of Preferred Stock Liabilities data on record, last reported at $2.2 billion in Q4 2024.

  • For Q4 2024, Preferred Stock Liabilities changed N/A year-over-year to $2.2 billion; the TTM value through Dec 2024 reached $2.2 billion, changed N/A, while the annual FY2024 figure was $2.2 billion, 4.53% up from the prior year.
  • Preferred Stock Liabilities reached $2.2 billion in Q4 2024 per CAI's latest filing, up from $2.2 billion in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $2.2 billion in Q4 2024 and bottomed at $2.2 billion in Q2 2024.